Daiichi Sankyo: Leukemia, Myeloid, Acute trials

The registry lists 20 Leukemia, Myeloid, Acute studies with Daiichi Sankyo as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 12Phase 2 6Phase 3 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionRecruitingNCT06824168Phase 2
• Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT03671564Phase 1Results posted
• Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)TerminatedNCT03552029Phase 1Results posted
• DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)TerminatedNCT03110354Phase 1Results posted
• Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) MutationCompletedNCT02984995Phase 2Results posted
• Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02834390Phase 1Results posted
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)CompletedNCT02668653Phase 3Results posted
• Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)TerminatedNCT02319369Phase 1Results posted
• (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD PositiveCompletedNCT02039726Phase 3Results posted
• Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01565668Phase 2Results posted
• Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT01349049Phase 1/2Results posted
• Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)CompletedNCT00989261Phase 2Results posted
• A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 StatusCompletedNCT00462761Phase 1Results posted
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLActive, not recruitingNCT06578247Phase 3
• Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodActive, not recruitingNCT03793478Phase 1/2
• Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive QuizartinibNo longer availableNCT03746912
• Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT03723681Phase 1
• A Study of PLX51107 in Advanced MalignanciesTerminatedNCT02683395Phase 1
• A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)CompletedNCT01468467Phase 1
• A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT01390337Phase 1